fbpx

Lymphoma Knowledge Hub

Examining Palliative Care Utilization Among Hospitalized Patients with Diffuse Large B-Cell Lymphoma

Noting a lack of data on palliative care in patients with diffuse large b-cell lymphoma (DLBCL), researchers, led by Inimfon Jackson, MD, MPH, PhD,...

CD30 Expression Associated With Diffuse Large B-Cell Lymphoma Prognosis

In a study published in the Journal of Oral Pathology & Medicine, researchers examined the prognostic value of varying CD30 expressions in patients with...

R-CHOP With or Without Molecule-Directed Agents in Patients with Diffuse Large B-Cell Lymphoma

In a review of trials on the addition of molecular targeted agents (MTAs) to the rituximab, cyclophosphamide, hydroxydaunorubicin hydrochloride, vincristine, and prednisone (R-CHOP) treatment...

Intratumoral Lymphocytes in Diffuse Large B-Cell Lymphoma (DLBCL) Prognosis Predictions

A study published in Leukemia & Lymphoma examined the prognostic potential of regulatory t-cells (Tregs) in patients with diffuse large B-cell lymphoma (DLBCL). The...

JULIET: Long-Term Outcomes of Tisagenlecleucel in Patients with Relapsed/Refractory Aggressive B-Cell Lymphomas

The JULIET trial of tisagenlecleucel, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, reported a best overall response rate (ORR) of 52% and...
Diagnostic form with lymphoma.

Venetoclax Plus Dose–Adjusted EPOCH-R in Patients with Aggressive B-Cell Lymphoma

In a clinical trial published in The Lancet Haematology, researchers reported that venetoclax with dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) demonstrated...

Single-Agent and Combined Everolimus and Panobinostat in Relapsed/Refractory DLBCL

Researchers sought to evaluate everolimus, a mammalian target of rapamycin inhibitor (mTORi), an panobinostat, the histone deacetylase inhibitor (HDACi), in patients with relapsed/refractory (R/R)...
Advertisement

Journal Reading List

Advertisement
Advertisement